Alexion Pharmaceuticals, Inc. (ALXN) 182.50 (0%)12-31 19:00 Open:181.04 High:182.67 Volume:3 Pre. Close:182.5 Low:180.21 Market Cap:0(M) Technical analysis Short term Mid term Targets6-month :1-year : ResistsFirst :Second : Pivot price ...
A high-level overview of Alexion Pharmaceuticals, Inc. (ALXN) stock. View (ALXN) real-time stock price, chart, news, analysis, analyst reviews and more.
AstraZeneca ALEXION and the Alexion logo are registered trademarks of Alexion Pharmaceuticals, Inc. © 2025, Alexion Pharmaceuticals, Inc. All rights reserved.This website uses cookies to improve user experience and to improve performance and analyze traffic on this webpage. By clicking “Accept ...
The article reports that biotech company Alexion Pharmaceuticals will buy in cash and stock the rare-disease specialist Synageva BioPharma with $230 per share. Topics mentioned include the stock dip by Alexion and the increase of Synageva in the early trade, the bid in diversifying the market ...
Halozyme Therapeutics, Inc. (HALO): Free Stock Analysis Report Alexion Pharmaceuticals, Inc. (ALXN): Get Free Report Akari Therapeutics PLC (AKTX): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research ...
Today, a Director at Alexion Pharmaceuticals (NASDAQ: ALXN), Christopher J. Coughlin, bought shares of ALXN for $1.21M. This recent transaction increases
Alexion Pharmaceuticals(NASDAQ:ALXN) developed and distributes Soliris, its sole FDA-approved commercial drug, which treats two types of rare blood disorders. In October, the FDA awarded breakthrough therapy designation for ALXN1101, a new drug Alexion is developing to treat hypophosphatasia, or ...
Alexion stock has come under fire lately, but the company has a promising pipeline of orphan drugs that could prod others to consider a takeover.
Alexion Pharmaceuticals surged early Thursday after its new blood disease drug proved worthy when compared with its own biggest moneymaking medicine in a key trial, which could set the table for a patent extension.Video Categories Featured Videos Stock Market Today Industry Insights Investing Podcast ...
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) andStealth BioTherapeutics Corp(NASDAQ:MITO) today announced an agreement for an option to co-develop and commercialize elamipretide for mitochondrial diseases. Currently being evaluated in a Phase 3 study in people with primary mitochondrial myopathy (PMM) ...